Fenebrutinib in Relapsing MS: FENhance Trial Results Explained
About this episode
Experts discuss the FENhance trial results for fenebrutinib as a treatment for relapsing MS.
New Phase 3 data presented at the AAN conference 2026 provide compelling evidence that fenebrutinib may represent a high-efficacy oral treatment option for people living with relapsing multiple sclerosis. In this exclusive episode, leading experts Prof. Ludwig Kappos from University of Basel and Dr. Jiwon Oh from Barlo MS Centre join host Brett Drummond to unpack the full FENhance 1 & 2 trial results. Together, they explore: How fenebrutinib performed against teriflunomide in relapsing MS Why BTK inhibition continues to generate strong interest across the MS treatment landscape What the results reveal about relapse reduction, MRI outcomes, and disability progression What the safety profile of fenebrutinib looked like in this cohort of patients Listen for a deep dive into the science, clinical context, and future implications for MS care.
More episodes of The ECTRIMS Podcast
- How MRI and OCT are Changing Multiple Sclerosis Diagnosis, Prognosis, and Treatment
- Does the Label Given to My MS Disease Course Matter?
- Rehabilitation in MS and the Case for Early Intervention
- Fenebrutinib in PPMS: Insights from ACTRIMS Forum 2026
- Harnessing the Gut Microbiome in MS: From Insight to Intervention
- How well are we measuring cognition in MS?
Explore listener stats, chart rankings, contacts and more on the The ECTRIMS Podcast podcast page.